Drug Profile
Research programme: STAT3 transcription factor inhibitors - Moleculin Biotech
Alternative Names: CABE; caffeic acid benzyl ester; caffeic acid phenyl ester; CAPELatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Moleculin; University of Texas M. D. Anderson Cancer Center
- Developer Moleculin Biotech
- Class Caffeic acids; Cinnamates
- Mechanism of Action STAT3 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Psoriasis in USA (Topical)
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA (Topical)
- 15 Oct 2013 Development for Cancer and Psoriasis is ongoing in USA